Still calculating financial ratios manually?
Stop wasting time — let the computer do it!
Ovid Therapeutics Inc. (OVID) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
441 NINTH AVENUE, 14TH FLOOR NEW YORK, NY 10001 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2026 Q1 | 12/31/2025 Q4 | 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 90,447 | 25,603 | 38,347 | 42,996 | 53,075 | 62,712 | |||
| Cash and cash equivalent | 13,153 | 20,611 | 28,415 | 21,136 | 26,301 | 15,017 | |||
| Short-term investments | 56,482 | 4,992 | 9,932 | 21,860 | 26,774 | 47,695 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 20,812 | ||||||||
| Other undisclosed current assets | (16,079) | 3,221 | 3,742 | 2,925 | 2,865 | 3,115 | |||
| Total current assets: | 74,368 | 28,824 | 42,089 | 45,921 | 55,940 | 65,827 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 11,610 | 11,916 | 12,215 | 12,509 | 12,797 | 13,080 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 252 | 269 | 285 | 346 | 433 | 509 | |||
| Long-term investments and receivables | 20,812 | 20,908 | 20,908 | 20,908 | 20,974 | 21,125 | |||
| Long-term investments | 20,812 | 20,908 | 20,908 | 20,908 | 20,974 | 21,125 | |||
| Intangible asset, including goodwill, after accumulated amortization | 38 | 100 | 155 | ||||||
| Intangible asset, excluding goodwill, after accumulated amortization | 38 | 100 | 155 | ||||||
| Other noncurrent assets | 39 | 92 | 182 | ||||||
| Other undisclosed noncurrent assets | 43,892 | 1,931 | 1,931 | 1,893 | 1,831 | 1,776 | |||
| Total noncurrent assets: | 76,566 | 35,024 | 35,339 | 35,733 | 36,227 | 36,827 | |||
| TOTAL ASSETS: | 150,934 | 63,848 | 77,428 | 81,654 | 92,167 | 102,654 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 6,855 | 4,669 | 6,822 | 7,947 | 9,185 | 10,317 | |||
| Accounts payable | 1,956 | 1,710 | 3,950 | 1,950 | 3,191 | 2,710 | |||
| Accrued liabilities | 4,899 | 2,959 | 2,872 | 5,997 | 5,994 | 7,607 | |||
| Other undisclosed current liabilities | 1,433 | 2,127 | 2,102 | 1,360 | 1,337 | 1,313 | |||
| Total current liabilities: | 8,288 | 6,796 | 8,924 | 9,307 | 10,522 | 11,630 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 11,986 | 12,354 | 12,715 | 13,070 | 13,419 | 13,762 | |||
| Operating lease, liability | 11,986 | 12,354 | 12,715 | 13,070 | 13,419 | 13,762 | |||
| Other undisclosed noncurrent liabilities | 972 | ||||||||
| Total noncurrent liabilities: | 11,986 | 12,354 | 12,715 | 13,070 | 13,419 | 14,734 | |||
| Total liabilities: | 20,274 | 19,150 | 21,639 | 22,377 | 23,941 | 26,364 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 130,660 | 44,698 | 55,789 | 59,276 | 68,226 | 76,290 | |||
| Common stock | 130 | 71 | 71 | 71 | 71 | 71 | |||
| Additional paid in capital | 452,445 | 376,129 | 375,005 | 373,786 | 372,489 | 371,228 | |||
| Accumulated other comprehensive income (loss) | (202) | (126) | (69) | (47) | (35) | 36 | |||
| Accumulated deficit | (321,713) | (331,376) | (319,218) | (314,533) | (304,299) | (295,045) | |||
| Other undisclosed equity, attributable to parent | (1) | ||||||||
| Other undisclosed equity | 1 | ||||||||
| Total equity: | 130,660 | 44,698 | 55,789 | 59,277 | 68,226 | 76,290 | |||
| TOTAL LIABILITIES AND EQUITY: | 150,934 | 63,848 | 77,428 | 81,654 | 92,167 | 102,654 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2026 Q1 | 12/31/2025 Q4 | 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 718 | 132 | 6,272 | 130 | 76 | 173 | ||
| Cost of revenue (Cost of Product and Service Sold) | (17) | (17) | (99) | (141) | ||||
| Other undisclosed gross profit | (613) | |||||||
| Gross profit: | 701 | 115 | 6,173 | (11) | (537) | 173 | ||
| Operating expenses | (13,011) | (12,655) | (11,345) | (12,680) | (10,798) | (13,399) | ||
| Other undisclosed operating income | 17 | 17 | 99 | 141 | 613 | |||
| Operating loss: | (12,293) | (12,523) | (5,073) | (12,550) | (10,722) | (13,226) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 21,957 | 365 | 389 | 2,315 | 1,469 | (780) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | 9,664 | (12,158) | (4,684) | (10,235) | (9,253) | (14,006) | ||
| Other undisclosed loss from continuing operations before income taxes | (1) | |||||||
| Net income (loss) available to common stockholders, basic: | 9,663 | (12,158) | (4,684) | (10,235) | (9,253) | (14,006) | ||
| Other undisclosed net income available to common stockholders, diluted | 273 | 458 | ||||||
| Net income (loss) available to common stockholders, diluted: | 9,936 | (12,158) | (4,684) | (10,235) | (8,795) | (14,006) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2026 Q1 | 12/31/2025 Q4 | 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 9,663 | (12,158) | (4,684) | (10,235) | (9,253) | (14,006) | ||
| Comprehensive income (loss): | 9,663 | (12,158) | (4,684) | (10,235) | (9,253) | (14,006) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (76) | (57) | (12) | (12) | (70) | 48 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 9,587 | (12,215) | (4,696) | (10,247) | (9,323) | (13,958) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.
An easy way to get professional financial analysis in one click
Load financial statements → click "Get report" → Your report is ready.
No financial analysis knowledge required!